Nevro to Report First Quarter 2021 Financial Results
Company to Host Conference Call on Wednesday, May 5, 2021, at 1:30 pm PT / 4:30 pm ET
News provided by
Share this article
Share this article
REDWOOD CITY, Calif., April 7, 2021 /PRNewswire/ Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021.
Management will host a conference call on May 5, 2021 to discuss first quarter 2021 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET. Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 6194499. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro s website at
Operator
Good afternoon, my name is Katherine and I ll be your conference operator today. At this time, I would like to welcome everyone to the Nevro s Fourth Quarter 2020 Financial Results Conference Call. [Operator Instructions]
I would now like to turn the call over to Julie Dewey for introductory remarks. Thank you. Please go ahead.
Julie Dewey
Vice President, Investor Relations & Corporate Communications
Good afternoon and welcome to Nevro s fourth-quarter 2020 earnings conference call. We appreciate you joining us. I am Julie Dewey, Nevro s VP of IR, and Corporate Communications. With me today are Keith Grossman, Chairman, CEO, and President, and Rod MacLeod, Chief Financial Officer.
Share this article
Share this article
REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ended December 31, 2020 after the market closes on February 24, 2021.
Management will host a conference call on February 24, 2021 to discuss fourth quarter and full-year 2020 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET. Investors interested in listening to the call may do so by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally, using Conference ID: 1353779. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro s website at
Nevro is proud to continue our longstanding commitment to investing in the field of neuromodulation and expanding our growing body of clinical evidence, said D. Keith Grossman, Chairman, CEO and President of Nevro. We are excited for Dr. Petersen and Dr. Kapural to share the significant data from the SENZA-PDN and the SENZA-NSRBP trials at NANS, reflecting our commitment to helping physicians treat underserved patient populations suffering from debilitating chronic pain. Additionally, we are pleased the many clinical investigators studying HF10 will have the opportunity to present the results of numerous additional studies we are conducting globally.
Key amongst these presentations will be data for the SENZA-Painful Diabetic Neuropathy (PDN) randomized clinical trial (RCT) and a first look at results from the Non-Surgical Refractory Back Pain (NSRBP) RCT:
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date
News provided by
Share this article
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company has submitted a pre-market approval supplement to the U.S. Food and Drug Administration (FDA) to seek approval of its Senza® System for the treatment of chronic pain associated with Painful Diabetic Neuropathy (PDN).